Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: 01 June 2009
More about this publication?
- Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.